Peptide Immunotherapy Platform

About Sift Biosciences

Sift Biosciences is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, Massachusetts, with operations in San Carlos, California. The company is pioneering a novel class of T-cell modulators derived from bacteria and viruses, aiming to harness pre-existing microbial immunity to fight cancer and autoimmunity. Its proprietary platform integrates AI-driven discovery with experimental immunology to identify peptides that activate memory T cells against disease targets. Spun out of UC Berkeley, the company is led by a team with deep expertise in computational biology, immunology, and drug development.

About Sift Biosciences

Sift Biosciences is a private, preclinical-stage biotech founded in 2018 and based in Cambridge, Massachusetts, with operations in San Carlos, California. The company is pioneering a novel class of T-cell modulators derived from bacteria and viruses, aiming to harness pre-existing microbial immunity to fight cancer and autoimmunity. Its proprietary platform integrates AI-driven discovery with experimental immunology to identify peptides that activate memory T cells against disease targets. Spun out of UC Berkeley, the company is led by a team with deep expertise in computational biology, immunology, and drug development.

Therapeutic Areas